Announcements Trials
Browse Landscape

Phase

Phase 1 58Phase 2 57Phase 1/2 35Phase NA 17Phase 3 17Phase EARLY_PHASE1 7Phase 2/3 2Phase 4 1

Status

Recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Breast Neoplasms 60Neoplasms 24Prostatic Neoplasms 21Multiple Myeloma 17Carcinoma, Non-Small-Cell Lung 15Carcinoma, Hepatocellular 15Stomach Neoplasms 11Papillomavirus Infections 11Lung Neoplasms 11Colorectal Neoplasms 11Melanoma 9Pain, Postoperative 7Neoplasm Metastasis 7Leukemia, Myeloid, Acute 7Waldenstrom Macroglobulinemia 6Lymphoma, Non-Hodgkin 6Leiomyoma 6Hematologic Neoplasms 6Brain Neoplasms 6Smoking Cessation 5Precursor Cell Lymphoblastic Leukemia-Lymphoma 5Polycystic Ovary Syndrome 5Pain 5Lymphoma 5Glioma 5Carcinoma, Renal Cell 5Venous Thromboembolism 4Uterine Cervical Neoplasms 4Urinary Bladder Neoplasms 4Tobacco Use Disorder 4

Interventions

enfortumab vedotin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 4 × Carcinoma, Transitional Cell × 1 year × Clear all
NCT06862219 2026-05-28

A Safety Study of Enfortumab Vedotin in Indian Adults With Urothelial Cancer

Astellas Pharma Inc

Phase 4 Recruiting
100 enrolled
Genitourinary

Carcinoma, Transitional Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡